首页> 美国卫生研究院文献>BMJ Open >Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control phase I/II trial
【2h】

Allogeneic human umbilical cord-derived mesenchymal stem/stromal cells for chronic obstructive pulmonary disease (COPD): study protocol for a matched case–control phase I/II trial

机译:同种异体人脐带衍生的间充质茎/基质细胞用于慢性阻塞性肺疾病(COPD):匹配案例控制的研究方案I / II阶段试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The global prevalence of chronic obstructive pulmonary disease (COPD) is increasing, and it has become a major public health burden worldwide, including in Vietnam. A large body of preclinical and clinical studies supports the safety of mesenchymal stem/stromal cells (MSCs) in the treatment of lung injury, including COPD. The aim of this trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) as a supplementary intervention in combination with standard COPD medication treatments in patients with moderate-to-severe COPD based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019 and Vietnam Ministry of Health’s guidelines.
机译:慢性阻塞性肺病(COPD)的全球患病率正在增加,它已成为全世界的主要公共卫生负担,包括在越南。大量的临床前和临床研究支持间充质茎/基质细胞(MSCs)的安全性在治疗肺损伤,包括COPD。该试验的目的是探讨同种异体脊髓衍生的MSCs(UC-MSCs)的安全性和潜在治疗疗效,作为辅助干预与基于中度至严重的COPD患者的标准COPD药物治疗组合2019年慢性阻塞性肺病(黄金)和越南卫生部准则的全球倡议。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号